News
Discover the latest news stories, blog posts and publications from Cobra's expert team
Posts about
DNA
BLOG: COVID-19 Vaccine Hopes and Hurdles
Cobra has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production...
Cobra Biologics has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production of plasmid DNA and viral vaccines. This blog aims to give a short introduction into the different types of vaccines that are in use, including the platform approaches relating to these two candidates and to highlight some of the potential manufacturing and
Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project
£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields.
Keele and Leeds, UK, 30th October 2018: Cobra Biologics and the University of Leeds have been awarded £100,000 to investigate the effects of hydrodynamic force on the structure and biological integrity of viral vector gene therapy products. This proof-of-concept grant is funded by the Biotechnology and Biological Sciences Research Council (BBSRC) Networks in Industrial Biotechnology and Bioenergy (NIBB) BioProNET, a network that brings together
Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK
Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK
Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments Cobra Biologics, an international CDMO of biologics and pharmaceuticals, announced that it has been awarded £2.6 million ($3.4 million) capital infrastructure investment by
BLOG: Cobra Expansion Vlog
As We Embark On A £15m / 165m SEK / $19m Gene Therapy Manufacturing Operations Expansion
Following the news of Cobra's expansion earlier this week, Chief Executive Peter Coleman took to social media to express his gratitude for the fantastic response we have recieved and to highlight the importance of investing in gene therapy: